Wednesday - May 14, 2025
DETROIT, Oct. 2, 2024 /PRNewswire/ -- Ambetter from Meridian, a product offered by a Centene Corporation (NYSE: CNC) company, which provides insurance to under-insured and uninsured populations through the federal Health Insurance Marketplace®, will offer a variety of affordable health insurance plans to Michiganders in 34 counties in plan year 2025. Open enrollment for the Health Insurance Marketplace for Michigan runs from Nov. 1, 2024, through Jan. 15, 2025. Enroll by Dec. 15, 2024, for coverage starting Jan. 1, 2025.
"With food, gas, utility and housing costs continuing to rise throughout Michigan, many individuals and families are looking for ways to save money and meet their basic needs," said Plan President and Chief Executive Officer Patty Graham. "That's why we are proud to offer Ambetter from Meridian, a budget-friendly, high-quality, comprehensive coverage health plan that fits all ages and stages of life."
Ambetter from Meridian offers its members access to quality care, convenient services and valuable rewards. The 2025 benefits and offerings include:
Below is the full list of counties in which Ambetter from Meridian will be offered in 2025:
Michigan residents interested in learning more about Ambetter from Meridian or enrolling in a health plan during the open enrollment period may visit ambetterhealth.com/en/mi/.
About Ambetter from Meridian
Ambetter from Meridian serves under-insured and uninsured populations through the federal Health Insurance Marketplace®. Ambetter from Meridian is underwritten by Meridian Health Plan of Michigan, Inc., which is a Qualified Health Plan issuer in Michigan. For more information, visit ambetterhealth.com/en/mi/. This is a solicitation for insurance. For information on your right to receive an Ambetter from Meridian plan free of discrimination, or your right to receive language, auditory and/or visual assistance services, please visit ambetterhalth.com/en/ and scroll to the bottom of the page.
Last Trade: | US$59.47 |
Daily Change: | 0.50 0.85 |
Daily Volume: | 5,618,322 |
Market Cap: | US$30.020B |
April 25, 2025 February 24, 2025 February 04, 2025 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load